CR8825A - Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6 - Google Patents

Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6

Info

Publication number
CR8825A
CR8825A CR8825A CR8825A CR8825A CR 8825 A CR8825 A CR 8825A CR 8825 A CR8825 A CR 8825A CR 8825 A CR8825 A CR 8825A CR 8825 A CR8825 A CR 8825A
Authority
CR
Costa Rica
Prior art keywords
indolilalkylamine
hydroxitriptamine
metabolites
ligands
disorders
Prior art date
Application number
CR8825A
Other languages
English (en)
Spanish (es)
Inventor
Wang Youchu
Cheng Shaw Chia
Charles Bernotas Ronald
Paul Wang Cheng-Chiee
Cai Ping
Wang Zhi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35033547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8825A publication Critical patent/CR8825A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR8825A 2004-06-23 2006-12-21 Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6 CR8825A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58229004P 2004-06-23 2004-06-23

Publications (1)

Publication Number Publication Date
CR8825A true CR8825A (es) 2007-08-28

Family

ID=35033547

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8825A CR8825A (es) 2004-06-23 2006-12-21 Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6

Country Status (19)

Country Link
US (1) US7498327B2 (enExample)
EP (1) EP1758898A1 (enExample)
JP (1) JP2008504267A (enExample)
KR (1) KR20070041514A (enExample)
CN (1) CN1976928A (enExample)
AR (1) AR049449A1 (enExample)
AU (1) AU2005258025A1 (enExample)
BR (1) BRPI0512540A (enExample)
CA (1) CA2570818A1 (enExample)
CR (1) CR8825A (enExample)
EC (1) ECSP067096A (enExample)
IL (1) IL180198A0 (enExample)
MX (1) MX2007000182A (enExample)
NO (1) NO20070065L (enExample)
PA (1) PA8637801A1 (enExample)
PE (1) PE20060303A1 (enExample)
RU (1) RU2006146923A (enExample)
TW (1) TW200606148A (enExample)
WO (1) WO2006002125A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
DK1455779T3 (da) * 2001-12-20 2006-10-30 Wyeth Corp Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
WO2004078719A1 (ja) * 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity

Also Published As

Publication number Publication date
AU2005258025A1 (en) 2006-01-05
ECSP067096A (es) 2007-02-28
US20060003945A1 (en) 2006-01-05
PA8637801A1 (es) 2006-06-02
KR20070041514A (ko) 2007-04-18
TW200606148A (en) 2006-02-16
BRPI0512540A (pt) 2008-03-25
WO2006002125A1 (en) 2006-01-05
IL180198A0 (en) 2007-06-03
AR049449A1 (es) 2006-08-02
MX2007000182A (es) 2007-03-23
JP2008504267A (ja) 2008-02-14
CA2570818A1 (en) 2006-01-05
NO20070065L (no) 2007-01-04
US7498327B2 (en) 2009-03-03
EP1758898A1 (en) 2007-03-07
CN1976928A (zh) 2007-06-06
PE20060303A1 (es) 2006-05-19
RU2006146923A (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
UY28473A1 (es) Nuevos compuestos
UY28144A1 (es) Agentes terapéuticos
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
UY28752A1 (es) Agentes terapeuticos
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
GT200800214A (es) Antagonistas de los piridil amida de los canales de calcios de tipo t
UY28374A1 (es) Agentes terapéuticos
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CR9034A (es) Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad
CR8007A (es) Pirimidinonas sustituidas
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
UY31065A1 (es) Heterociclos ciclicos
CR8544A (es) Compuestos de quinolina sustituidos
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)